

liraglutide daily. [Trade only: Xultophy 100/3.6: 100 units insulin degludec/mL; 3.6 mg liraglutide/mL in 3 mL multidose pen.] ▶♀?/?/? Teratogenicity reported in animal studies; Insufficient human teratogenicity data. ▶? \$\$\$\$\$■

### Diabetes-Related—DPP-4 inhibitors

**ALOGLIPTIN (Nesina) DM, Type 2:** 25 mg PO daily. [Generic/Trade: Tabs 6.25, 12.5, 25 mg.] ▶K ⊕ ♀?/?/? ▶? \$\$\$\$\$

**LINAGLIPTIN (Tradjenta, \*Trajenta) DM, Type 2:** 5 mg PO once daily. [Trade only: Tab 5 mg.] ▶L ♀?/?/? ▶? \$\$\$\$\$

**SAXAGLIPTIN (Onglyza) DM, Type 2:** 2.5 or 5 mg PO daily. [Trade only: Tabs 2.5, 5 mg.] ▶LK ⊕ ♀?/?/? ▶? \$\$\$\$\$

**SITAGLIPTIN (Januvia) DM, Type 2:** 100 mg PO daily. [Trade only: Tabs 25, 50, 100 mg.] ▶K ⊕ ♀?/?/?R ▶? \$\$\$\$\$

### Diabetes-Related—GLP-1 agonists

**DULAGLUTIDE (Trulicity) DM, Type 2:** Start 0.75 mg SC once weekly. May increase to 1.5 mg SC once weekly. [Trade only: 0.75, 1.5 mg single-dose pen; 0.75, 1.5 mg single-dose prefilled syringe.] ▶proteolysis ♀?/?/? ▶? \$\$\$\$\$■

**EXENATIDE (Byetta, Bydureon Bcise) DM, Type 2, adjunctive therapy:** Immediate-release: 5 mcg SC two times per day (within 1 h before the morning and evening meals, or 1 h before the two main meals of the day at least 6 h apart). May increase to 10 mcg SC two times per day after 1 month. Extended-release: 2 mg SC once weekly given any time of day without regard to meals. [Trade only: Byetta, prefilled pen (60 doses each) 5 mcg/dose, 1.2 mL; 10 mcg/dose, 2.4 mL. Bydureon (extended-release): 2 mg/prefilled pen (single-use). Bydureon Bcise (extended-release): 2 mg/single-dose autoinjector.] ▶K/proteolysis ⊕ ♀?/?/? ▶? \$\$\$\$\$■

**LIRAGLUTIDE (Victoza, Saxenda) DM, Type 2 or reduction in risk of major adverse CV events in DM, Type 2 with established CV disease (Victoza):** Start 0.6 mg SC daily for 1 week, then increase to 1.2 mg SC daily. May increase to 1.8 mg SC daily. **Chronic weight management (Saxenda):** Start 0.6 mg SC daily for 1 week, then increase at weekly intervals to effective dose of 3 mg SC daily. [Trade only (Victoza): Multidose pen (18 mg/3 mL) delivers doses of 0.6, 1.2, or 1.8 mg. Trade only (Saxenda): Multidose pen (18 mg/3 mL) delivers doses of 0.6, 1.2, 1.8, 2.4, or 3 mg.] ▶proteolysis ♀?/?/? (Victoza); X/X/X (Saxenda) ▶? \$\$\$\$\$■

**LIXISENATIDE (Adlyxin) DM Type 2, adjunctive therapy:** Start 10 mcg SC daily, after 14 days increase to 20 mcg SC daily. Administer within 1 h before first meal of the day. [Trade only: multidose pens: 50 mcg/mL (3 mL pen) delivers 10 mcg/dose; 100 mcg/mL (3 mL pen) delivers 20 mcg/dose.] ▶proteolysis ⊕ ♀?/?/? Evidence of teratogenicity in animals; insufficient human teratogenicity data. ▶? \$\$\$\$\$

**SEMAGLUTIDE (Ozempic) DM, Type 2:** Start 0.25 mg SC weekly for 4 weeks, then increase to 0.5 mg SC weekly. May increase to 1 mg SC weekly. [Trade only: Multidose pen (2 mg/1.5 mL) delivers doses of 0.25, 0.5 mg per injection or 1 mg per injection.] ▶♀?/?/? ▶■